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Abstract
Background: Achilles tendinopathy is a painful musculoskeletal condition that is common among athletes, and
which limits training capacity and competitive performance. The lack of biomarkers for tendinopathy limits research
into risk factors and also the evaluation of new treatments. Cytokines and growth factors involved in regulating the
response of tendon cells to mechanical load have potential as biomarkers for tendinopathy.
Methods: This case–control study compared serum concentration of cytokines and growth factors (TNF-α, IL-1β,
bFGF, PDFG-BB, IFN-γ, VEGF) between individuals with chronic Achilles tendinopathy and controls. These were
measured in fasting serum from 22 individuals with chronic Achilles tendinopathy and 10 healthy controls. Results
were analysed in relation to gender and physical activity pattern.
Results: TNF-α concentration was lower in the entire tendinopathy group compared with the entire control group;
none of the other cytokines were significantly different. TNF-α levels were nevertheless highly correlated with the
other cytokines measured, in most of the subgroups. Analysed by gender, TNF-α and PDGF-BB concentrations were
lower in the female tendinopathy group but not the male tendinopathy group. A trend was seen for lower IL-1β in
the female tendinopathy group. Physical activity was correlated with TNF-α, PDGF-BB and IL-1β to varying extents
for control subgroups, but not for the female tendinopathy group. No correlations were seen with BMI or duration
of symptoms.
Conclusions: This pilot study indicates a lower level of TNF-α and PDGF-BB, and to some extent IL-1β among
females, but not males, in the chronic phase of Achilles tendinopathy. It is suggested that future studies on
tendinopathy biomarkers analyse male and female data separately. The lack of correlation between cytokine level
and physical activity in the female tendinopathy group warrants further study.
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What is known about the subject
Tendinopathy has a lifetime incidence of more than
50 % in middle distance runners and presents a signifi-
cant barrier to optimal performance in many elite sports.
Much work has focussed on cytokine and growth factor
expression at the tissue level, however, this approach is
not suitable for longitudinal studies with multiple data
collection points due to the trauma induced by the bi-
opsy. Serum levels of cytokine expression overcomes this
limitation but has received little research attention.
What this study adds to existing knowledge
In this study, we found lower levels of TNF-α and
PDGF-BB among females with chronic Achilles tendino-
pathy. Curiously, the association between physical activ-
ity and cytokine levels seen in the female control group
was absent in the female tendinopathy group. These
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ject numbers, however, they provide direction and justi-
fication for further studies in this area.
Clinical relevance
Potential biomarkers for chronic Achilles tendinopathy
include TNF-α and PDGF-BB. These findings require
verification in larger samples and should be extended to
populations with recently developed tendinopathy.
Background
Achilles tendinopathy is commonly seen in sports medi-
cine and general practice. The cumulative lifetime inci-
dence is 6 % in the non-athletic general population and
52 % in middle distance runners [1]. Contributing fac-
tors among athletes can include a sudden increase in
loading [2, 3], a hard training surface [4], lower limb bio-
mechanics [5] and calf muscle weakness [6]. Among
non-athletic individuals, systemic factors such as dia-
betes [7] and blood lipids [8] may decrease the capacity
of the tendon to tolerate everyday loads and contribute
to tendinopathy in the absence of high tendon loading.
Serum biomarkers such as tumour necrosis factor
alpha (TNF-α) are useful for monitoring disease severity
and can even help to confirm a suspected diagnosis. For
example, certain markers discriminate persons with bi-
polar disorder from controls [9]. In addition, an associ-
ation between TNF-α and objective measures of
depression and fatigue is shown in studies of chronic ob-
structive pulmonary disease (COPD) [10]. The TNF-α
system is also strongly involved in inflammatory disor-
ders such as inflammatory bowel disease and rheuma-
toid arthritis. Blood levels of both TNF-α and the
soluble form of tumour necrosis factor receptor 1
(sTNFR1) [11] are increased among inflammatory bowel
disease patients. sTNFR1 is generated when transmem-
brane TNFR1 is cleaved and the extracelluar receptor
fragment is released [12]. At low concentrations,
sTNFR1 stabilises the structure of TNF-α and slows its
decay, while at higher concentrations it acts as a com-
petitive antagonist for TNF-α action [13]. TNF receptor
levels also correlate with disease activity for inflamma-
tory bowel disease patients [14], and in rheumatoid arth-
ritis TNF-α levels are increased in the synovial fluid of
affected joints [15] and serum sTNFR1 levels are also el-
evated [16]. The presence of TNF-α and its two recep-
tors has been confirmed in human Achilles tendon [17].
There is very little information on the effects of
marked exercise on levels of TNF-α. In one study, in
which the effects of heavy resistance exercise was evalu-
ated for 30 resistance trained men, an initial increase but
later, at recovery, a decrease in blood TNF-α levels was
noted [18]. These authors also concluded that neuro-
muscular electrical stimulation appeared to prevent thedecline in the circulating TNF-α that was observed dur-
ing recovery [18]. In a study by Andersson and co-
workers, it was found that the levels of TNF-α signifi-
cantly increased after endurance physical exercise in
non-athletes [19]. Likewise, it was found that there were
increases in levels of TNF-α and other cytokines directly
after 90-min soccer games in elite female players but
that the levels were normalized within 21 h [20]. In a
study on horses it was noted that the TNF-α blood level
did not change in response to exercise competition but
the authors concluded that circulating cytokines may
after all be predictive of athletic performance [21]. In an-
other study the mechanisms underlying overtraining
syndrome for men was discussed and it was suggested
that increased cytokine productions might be involved
in this syndrome [22].
Only two human studies have investigated serum bio-
markers for tendinopathy. In one study, serum levels of
sTNFR1 and brain-derived neurotropic factor (BDNF)
were no different between groups with and without ten-
dinopathy [23]. However, gender-dependent correlations
with physical activity levels were seen in the tendinopa-
thy group but not in the control group. The other study
investigated serum levels of oxidative derivatives of an
omega-6 fatty acid (linoleic acid), which are known as
oxylipins [24]. Other potentially interesting biomarkers
for musculoskeletal diseases [25], such as tendinopathy,
include TNF-α, interleukin 1 beta (IL-1β), basic fibro-
blast growth factor (bFGF), interferon gamma (IFN-γ),
platelet derived growth factor BB (PDGF-BB) and vascu-
lar endothelial growth factor (VEGF).
It is a drawback that there is so little information con-
cerning serum biomarkers in tendinopathy, as this con-
dition is so frequently occurring among sports active
individuals. Therefore, the aim of this study was to com-
pare concentrations in serum of the cytokines referred
to above between patients with Achilles tendinopathy
and healthy controls. As the pattern of physical activity
of patients with Achilles tendinopathy can influence bio-
marker concentrations [23], correlations with physical
activity level were explored, as were correlations with
two other factors [body mass index (BMI) and pain
symptom length]. The hypothesis was that certain bio-
marker/s might show a special pattern for tendinopathy
patients as compared with control persons.Methods
This project was approved by the Committee of Ethics
at the Faculty of Medicine, Umeå University, and by the
Regional Ethical Review Board in Umeå (04–157 M). All
procedures were conducted according to the principles
of the declaration of Helsinki. All participants gave writ-
ten, informed consent.
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cine Unit at Umeå University for management of
chronic Achilles tendon pain were included in this study.
All individuals had a diagnosis of mid-portion Achilles
tendinopathy established by an experienced orthopaedic
surgeon (HA). Diagnostic criteria included exercise-
related pain in the Achilles tendon, localised 2 to 6 cm
proximal to the calcaneal attachment. Only individuals
with gradual onset of pain were included to avoid the
possibility of including cases of partial rupture. The in-
cluded patients had been referred to the Sports Medi-
cine Unit following unsuccessful treatment of their
condition with their local clinician (e.g. GP, physiother-
apist). Previous treatments reported by these patients
were rest from aggravating activities and heavy-load ec-
centric training. Ten control individuals with no history
of Achilles tendon pain were recruited from the local
community.
Both patients and controls had an ultrasound examin-
ation by the same orthopaedic surgeon (HA) using an
Acuson Sequoia 512 (Siemens AG, Berlin, Germany) fit-
ted with 8–13 MHz linear array transducer. From the
prone position with both feet hanging off the end of the
bed, the right and left Achilles tendons were examined
using grey-scale and colour Doppler ultrasound. Charac-
teristic features of tendinopathy were present in the pa-
tient group (increased anterior-posterior diameter,
hypoechoic regions, and the loss of the clear demarca-
tion between the anterior border of the tendon and
Kager’s fat pad). Colour Doppler showed increased vas-
cularity in the affected region of the painful tendon. All
control participants had normal ultrasound examination
findings.
Blood samples were collected in an identical manner
for the tendinopathy and control groups. Blood was col-
lected in the morning following an overnight fast in a
serum separating tube, which was clotted at room
temperature for 30 min and then centrifuged at 1300 × g
for 10 min. Serum aliquots were stored at −80 °C await-
ing analysis and did not undergo repeated freeze-thaw
cycles.
Serum aliquots were thawed on ice immediately prior
to analysis. Cytokine concentrations (TNF-α, IL-1β,
bFGF, IFN-γ, PDGF-BB, and VEGF) were quantified
using the Human Cytokine Group 1, 6-plex assay (cata-
logue number: X50007Z13H) on a Bio-Plex 200 Suspen-
sion Array System (Bio-Rad, Hercules, California, USA),
according to the manufacturers instructions. Measure-
ments were made in duplicate wells and all samples were
tested on a single 96-well plate, which eliminated the
possibility of plate-to-plate variation.
The limit of detection, defined as 2 standard deviations
(SD) above the mean background fluorescence, is pro-
vided by the manufacturer based on measurement of 10replicate wells containing all reagents except the cyto-
kine of interest. The limit of detection for TNF-α is
3.0 pg/mL, for IL-1β 0.8 pg/mL, for bFGF 6.8 pg/mL,
for IFN-γ 19.3 pg/mL, for PDGF-BB 1.0 pg/mL, and for
VEGF 0.5 pg/mL.
The physical activity level of all participants was quan-
tified using the Past Year Physical Activity Questionnaire
(PYT-PAQ). The questionnaire prompts participants to
estimate the frequency (months/year, days/week), dur-
ation (hours/day) and perceived intensity (sedentary,
light, moderate, heavy) of occupational, household, and
recreational activities over the past 12-months. These
questionnaires are coded according to the typical meta-
bolic cost of each activity to yield a metabolic equivalent
(MET) of physical activity that is expressed in MET-
hours/week.
The reproducibility of the MET-hours/week estimates
from questionnaires completed 9-week apart is 0.70
(Spearman’s rank correlation coefficient) for occupa-
tional activity, 0.65 for household activitity, 0.73 for rec-
reational activity and 0.64 for total activity [26]. This
questionnaire has also been validated using 4 × 7-day
physical activity diaries and 4 × 7-day accelerometer
data, with the 4-time points in different weather seasons.
Questionnaire validity against physical activity logs
(intraclass correlation coefficient (ICC) = 0.42, 95 % CI =
0.28 to 0.54)) and against accelerometer data (ICC = 0.18
(95 % CI = 0.03 to 0.32) is comparable to other physical
activity questionnaires.
Due to the relatively small and uneven group numbers,
all analyses were conducted using non-parametric statis-
tics. Continuous variables were tested using the Mann–
Whitney U test. Significance level was set at p < 0.05 and
Bonferroni adjustment was not used due to the pilot na-
ture of this study.
The analysis was conducted first using all data points
and then repeated following removal of any cytokine
analysis result with a coefficient of variation (CV)
greater than 15 %. Results are reported as mean (SD)
throughout the manuscript unless otherwise indicated.
Analysis was performed using STATA/IC 13.1.
Results
Individuals with Achilles tendinopathy were well
matched to the control participants according to key
demographic variables (Table 1). There was a similar ra-
tio of men to women, with 60 and 68 % of the patient
and control group being male. Symptom data indicated
that all patients had chronic tendinopathy as the shortest
duration was 3.5 months.
Serum concentration of TNF-α was significantly lower
in individuals with Achilles tendinopathy, when females
and males were grouped together, compared with the
entire control group (Table 2). No differences were
Table 1 Participant demographics
Achilles tendon status
Normal (n = 10) Tendinopathy (n = 22) p
Sex (male:female) 6:4 15:7 0.652
Age (years) 54.5 (8.4) 53.0 (10.8) 0.475
Height (cm) 172.1 (11.3) 175.2 (7.1) 0.416
Weight (kg) 82.5 (18.8) 86.9 (16.4) 0.490
BMI (kg/m2) 27.6 (3.8) 28.2 (4.2) 0.968
Physical activity (MET-hours/week)a 137.2 (29.1) 151.2 (54.2) 0.637
Pain: symptom duration (months) N/A 24 (IQR 8 to 24) Range 3.5 to 120
Data reported as mean (standard deviation (SD)) except symptom duration, which is given as median and interquartile range (IQR). aPhysical activity data missing
for 1 individual in control group and 2 individuals in tendinopathy group
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that were analysed. The findings were unchanged when
the analysis was repeated after excluding data with CV
>15 % (Table 3).
The mean CV for the cytokines analysis was 7.8 %
(TNF-α), 5.3 % (IL-1β), 8.5 % (bFGF), 6.9 % (IFN-γ),
1.1 % (PDGF-BB), and 5.9 % (VEGF). Sixteen data points
were removed due to a CV >15 %, which left 176 of the
original 192 data points. As described above, repeating
the analysis after removal of these data did not affect the
results.
When separated by gender, serum TNF-α and PDGF-
BB levels were lower in women with tendinopathy com-
pared to women in the control group (Table 4). There
was a non-significant trend for IL-1β to be lower in
women with tendinopathy (p = 0.059). In contrast, no
group differences were seen for men (p > 0.5 for all cyto-
kines). After excluding data with CV >15 % there was a
clear trend towards significance for a difference in
TNF-α levels between women with and without tendi-
nopathy (p = 0.053, Table 5). Significance testing for
PDGF-BB (p = 0.023) and IL-1β (p = 0.059) levels be-
tween women with and without tendinopathy
remained unchanged. The results for the men wereTable 2 Serum cytokine concentrations (all data points)
Achilles tendon status
Analyte (pg/mL) Normal (n = 10) Tendinopathy (n = 22) p-value
TNF-α 173.58 (64.98) 114.40 (45.17) 0.018
IL-1β 13.08 (3.38) 11.18 (2.99) 0.193
bFGF 67.72 (26.60) 66.34 (26.53) 0.968
INF-γ 180.70 (74.90) 141.89 (46.94) 0.371
PDGF-BB 12041.49 (2813.68) 11062.68 (3447.73) 0.088
VEGF 203.21 (129.25) 217.05 (123.28) 0.626unaffected by removal of data with CV >15 % (p > 0.3
for all cytokines).
As TNF-α was different between the tendinopathy and
control group, correlations with potential confounding
factors (physical activity, BMI, pain symptom duration)
were determined to further explore this finding (Table 6).
A significant correlation was seen between TNF-α and
physical activity level for all men, however, when exam-
ined by subgroup there was a correlation for the men of
the control group but not those of the tendinopathy
group. No other correlations were seen for physical ac-
tivity, BMI or pain symptom duration.
Analysis of potential confounding factors was repeated
for PDGF-BB (Table 7) and IL-1β (Table 8). There was
no correlation between PDGF-BB and physical activity
for all men, however, when examined by subgroup there
was a negative correlation for the men of the tendinopa-
thy group but not those of the control group. There was
no correlation between PDGF-BB and physical activity
for all women, however, when examined by subgroup
there was a positive correlation for the women of the
control group but not the tendinopathy group. There
was no correlation between IL-1β and physical activity
for all men, however, when examined by subgroup there
was a positive correlation for the men of the control
group but not the tendinopathy group. No correlations
were seen for PDGF-BB or IL-1β with BMI or pain
symptom duration.
A further question of interest was whether a system-
atic pattern of cytokine expression existed. Therefore, bi-
variate correlations between pairs of cytokines were
examined using Spearmans rho (ρ) with TNF-α as the
reference cytokine (Table 9). Strong correlations were
observed between TNF-α and IFN-γ among all sub-
groups of men and women. Strong correlations were ob-
served between TNF-α and bFGF, and between TNF-α
and VEGF in men but not women. Finally, correlations
between TNF-α and IL-1β, and between TNF-α and
Table 3 Serum cytokine concentrations (excluding observations with CV >15 %)
Achilles tendon status
Analyte (pg/mL) n Normal n Tendinopathy p-value
TNF-α 8 179.52 (62.30) 18 119.93 (47.35) 0.030
IL-1β 10 13.08 (3.38) 22 11.18 (2.99) 0.193
bFGF 9 68.42 (28.11) 18 70.12 (27.89) 0.643
INF-γ 9 171.65 (73.43) 21 147.58 (39.57) 0.769
PDGF-BB 10 12041.49 (2813.68) 22 11062.68 (3447.73) 0.088
VEGF 9 211.36 (134.34) 20 232.60 (117.48) 0.5093
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and tendinopathy groups were examined separately. A
limitation for this analysis was small group numbers.
Discussion
This study of serum biomarkers for Achilles tendinopa-
thy has three key findings. First, TNF-α levels were lower
in women with tendinopathy than women without tendi-
nopathy. Second, contrasting findings were seen for men
and women across a number of outcomes. For example,
PDGF levels were lower in women with tendinopathy
but not in males with tendinopathy, and IL-1β showed a
non-significant trend toward being lower in the female
tendinopathy group as well. Third, the physical activity
level correlated with TNF-α only for control men but
not for any of the other groups. The finding for TNF-α
was an unexpected finding as previous research mainly
points toward an increased activation of the TNF-α sys-
tem in tendinopathy and tendon overuse [17, 23, 27].
However, consistent with the findings in the present
study, Pingel and collaborators [28] found decreased
TNF-α mRNA levels in the most abnormal part of the
affected tendon in comparison to 3 cm proximal in the
same tendon. Together these data indicate that although
the TNF-α system appears to be involved in tendinopa-
thy, whether it is up or down regulated appears to de-
pend on several factors. These factors appear to include
whether measurement is made 1) at the mRNA or pro-
tein level, 2) in the tissue or blood, 3) of the cytokine it-
self, of its two receptors, or of the soluble receptorTable 4 Serum cytokine concentrations analysed by sex and tendon
Male
Analyte (pg/mL) Normal (n = 6) Tendinopathy (n = 15)
TNF-α 153.25 (65.81) 132.02 (30.06)
IL-1β 12.23 (3.79) 11.68 (2.08)
bFGF 76.64 (29.83) 72.54 (24.76)
INF-γ 168.99 (72.33) 150.93 (42.14)
PDGF-BB 11108.4 (3378.3) 11181.3 (2857.4)
VEGF 238.97(155.33) 240.2367 (130.653fragments. Importantly, it also appears as if the situation
varies according to gender.
The influence of potential confounding factors on
TNF-α levels was explored with correlation analysis in
the various subgroups. The data showed a strong rela-
tionship between physical activity and TNF-α in the
male control group. The same relationship was not seen
in the male tendinopathy, the female control or female
tendinopathy groups. It is well known that plasma TNF-
α (and also sTNFR1 and sTNFR2) rises following strenu-
ous and prolonged exercise (i.e. marathon running), and
that the peak is seen during the first hour after the race
[29]. In a study on the effects of 14-days of endurance
physical activity (cross-country skiing) it was found that
the levels of TNF-α increased significantly at week-1 and
week-2 of the exercise but that they returned to baseline
values during the recovery period [19]. The source of
this increase is unclear, although it has been shown that
neither blood mononuclear cells [30] nor skeletal muscle
[31] is the source. It has been suggested that prolonged
strenuous exercise causes gastrointestinal ischaemia,
which leads to endotoxin leakage into the circulation
and a secondary increase in TNF-α [32]. This is sup-
ported by evidence of no increase in serum or muscle
TNF-α during prolonged but non-exhaustive exercise
[33]. In contrast to exhaustive exercise, the transition to
habitual aerobic exercise reduces plasma TNF-α in
mildly overweight healthy women [34] whereas no effect
is seen following 12-weeks of strength training in obese
men [35] or obese hypertensive men and women [36],status (all data points)
Female
p Normal (n = 4) Tendinopathy (n = 7) p
0.586 204.09 (58.13) 76.65 (50.93) 0.014
0.938 14.35 (2.60) 10.12 (4.37) 0.059
0.815 54.35 (15.56) 53.049 (27.06) 0.850
0.876 198.26 (86.17) 122.53 (54.10) 0.257
0.640 13441.1 (613.2) 10808.5 (4737.1) 0.023
0.876 149.57 (59.24) 167.4 (95.6) 0.571
Table 5 Serum cytokine concentrations analysed by sex and tendon status (excluding observations with CV >15 %)
Male Female
Analyte (pg/mL) Normal Tendinopathy p Normal Tendinopathy p
TNF-α 167.65 (62.11) 135.77 (30.36) 0.301 199.29 (70.22) 78.72 (61.85) 0.053
5 13 3 5
IL-1β 12.23 (3.79) 11.68 (2.08) 0.938 14.35 (2.60) 10.12 (4.37) 0.059
6 15 4 7
bFGF 79.67 (32.30) 75.56 (25.30) 0.883 54.35 (15.56) 56.00 (2.26) 0.807
5 13 4 5
INF-γ 168.99 (72.33) 150.92 (42.14) 0.876 176.99 (91.78) 139.22 (34.25) 0.796
6 15 3 6
PDGF-BB 11108.4 (3378.3) 11181.3 (2857.4) 0.640 13441.1 (613.2) 10808.5 (4737.3) 0.023
6 15 4 7
VEGF 238.97 (155.33) 240.24 (130.65) 0.876 156.12 (70.7) 209.69 (70.28) 0.297
6 15 4 5
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fect of exercise on serum TNF-α is dependent upon the
intensity of exercise, whether it is a single bout or habit-
ual and also to some extent on the obesity level of the
participants. Of interest, several studies in this area note
a relationship between plasma TNF-α and VO2max [37].
It is reasonable to draw a parallel between VO2max and
physical activity (as measured in this study), as VO2max
and the questionnaire used in this study have previously
been shown to be moderately correlated (Spearman’s
rank correlation = 0.37) [26]. However, it is unclear why
the correlation between physical activity and TNF-α
seen in control men was not detected in the tendinopa-
thy group. It can be speculated that patients with tendi-
nopathy experience pain with physical activities such as
running and brisk walking, and therefore avoid these ac-
tivities. The level of total physical activity did not differ
between the tendinopathy and control group, however,Table 6 Spearman’s rank correlation between serum TNF-α and phy
Achilles tendon status (group
Total M AT M
Physical Activitya rho 0.5105 0.3846
p 0.025519 0.1745
n 19 14
BMIb rho −0.1338 −0.1607
p 0.5632 0.5672
n 19 14
Pain: symptom durationc rho 0.033514
p 0.9094
n 14
aMeasured in MET-hours/week, bmeasured in kg/m2, cmeasured in months
Note: M male, F female, AT Achilles tendinopathy
Physical activity score was missing for 2 men and 1 woman, symptom duration wasthe questionnaire used does not indicate the proportion
of physical activity that is taken at high, moderate and
low intensity. Notwithstanding this limitation, avoidance
of painful activities might explain why there was the dif-
ference in TNF-α level between females with and with-
out tendinopathy.
The association of potential confounders (physical ac-
tivity, BMI, pain symptom duration) with PDGF-BB and
IL-1β was also examined. Associations were only found
for physical activity (tendinopathy males and control fe-
males for PDGF-BB, control males for IL-1β), but inter-
estingly no associations were found for the most
noteworthy group – females with tendinopathy. The ex-
planation for this finding may be an interesting topic for
future research.
In studies such as the one we conducted, it is import-
ant to clarify the potential influence of confounding fac-
tors. In contrast to physical activity (for control men),sical activity, BMI, and symptom duration
ed by gender)
Control M Total F AT F Control F
0.9000 −0.2242 −0.6000 0.4000
0.0374 0.5334 0.2080 0.6000
5 10 6 4
−0.1429 0.2545 0.6071 0.2000
0.7872 0.4500 0.1482 0.8000




missing for 1 man with tendinopathy
Table 7 Spearman’s rank correlation between serum PDGF-BB and physical activity, BMI, and symptom duration
Achilles tendon status (grouped by gender)
Total M AT M Control M Total F AT F Control F
Physical Activitya rho −0.1895 −0.5868 0.7000 −0.0545 −0.4857 1.0000
p 0.4372 0.0274 0.1881 0.8810 0.3287 0.0000
n 19 14 5 10 6 4
BMIb rho −0.0831 −0.0536 −0.1429 0.2455 0.3214 0.0000
p 0.7202 0.8496 0.7872 0.4669 0.4821 1.000
n 21 15 6 11 7 4
Pain: symptom durationc rho 0.2995 −0.4383
p 0.2982 0.3253
n 14 7
aMeasured in MET-hours/week, bmeasured in kg/m2, cmeasured in months
Note: M male, F female, AT Achilles tendinopathy
Physical activity score was missing for 2 men and 1 woman, symptom duration was missing for 1 man with tendinopathy
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strated a relationship with serum TNF-α, PDGF-BB or
IL-1β. Therefore, in this study these do not appear to be
important confounding factors. It is also worthwhile not-
ing that the mean BMI of the participants was within
the overweight category (25 – 30 kg/m2) but also that
the two groups were well matched. Some previous stud-
ies in tendinopathy have shown that pain symptom dur-
ation is relevant, with one study finding that patellar
tendinopathy biopsies showing VEGF protein expression
were from individuals that had a shorter duration of
symptoms than biopsies without VEGF expression [38].
In this case, neither BMI nor symptoms duration appear
to be confounding factors for the cytokines and growth
factors measured.
Very little is known regarding the role of TNF-α sig-
nalling in tendinopathy, necessitating a broader view
across other research fields. The importance of the TNF-
α system in chronic pain diseases has been recently
shown in studies on humans and mice with arthritis;Table 8 Spearman’s rank correlation between serum IL-1β and phys
Achilles tendon status (grou
Total M AT M
Physical Activitya rho 0.0018 −0.4154
p 0.9943 0.1397
n 19 14
BMIb rho −0.0026 −0.0107
p 0.9911 0.9698
n 21 15
Pain: symptom durationc rho 0.2704
p 0.3497
n 14
aMeasured in MET-hours/week, bmeasured in kg/m2, cmeasured in months
Note: M male, F female, AT Achilles tendinopathy
Physical activity score was missing for 2 men and 1 woman, symptom duration wasanti-TNF treatment leads to a rapid inhibition of pain
responses in the central nervous system, with the effect
occurring much more rapidly than the anti-
inflammatory effect of TNF-α blockade [39]. In addition,
it is known that preconditioning with a short ischaemic
event reduces the severity of cerebral damage by a sub-
sequent severe ischaemic event, and that this effect is in-
duced by upregulation of sTNFR1 by TNF-α signalling
[40]. Transient activity of the TNF-α system may result
in a sustained increase in sTNFR1 expression [40].
Therefore, increased sTNFR1 expression, as is seen in
Achilles tendon biopsies [17], may increase sensitivity to
TNF-α stimulation as has been shown in other tissues
[41]. Therefore, it remains of interest to examine TNF-α
levels, as well as other cytokines, in the very early stages
of tendinopathy, which will be the focus of future re-
search endeavours.
A key finding was the contrast in results between men
and women. This included finding lower levels of TNF-α
(and a lower level in PDGF-BB and a trend for aical activity, BMI, and symptom duration
ped by gender)
Control M Total F AT F Control F
0.9000 0.1152 −0.2571 0.8000
0.0374 0.7514 0.6228 0.2000
5 10 6 4
−0.1429 −0.0091 0.0357 0.4000
0.7872 0.9788 0.9394 0.6000




missing for 1 man with tendinopathy
Table 9 Spearman correlations between TNF-α and other cytokines
Spearman’s correlations with TNF-α (grouped by gender and tendon status)
Analyte (pg/mL) Total M (n = 21) AT M (n = 15) Control M (n = 6) Total F (n = 11) AT F (n = 7) Control F (n = 4)
TNF-α rho 1 1 1 1 1 1
p
IL-1β rho 0.5182 0.2321 1.0000 0.7182 0.3571 0.8000
p 0.0161 0.4051 0.0000 0.0128 0.4316 0.2000
bFGF rho 0.6442 0.5286 0.9429 0.2091 0.3214 0.2000
p 0.0016 0.0428 0.0048 0.5372 0.4821 0.8000
INF-γ rho 0.7067 0.6416 0.8857 0.7182 0.6786 1.0000
p 0.0003 0.0099 0.0188 0.0128 0.0938 0.0000
PDGF-BB rho 0.1312 −0.2536 0.7143 0.7182 0.4286 0.4000
p 0.5709 0.3618 0.1108 0.0128 0.3374 0.6000
VEGF rho 0.6844 0.5786 1.0000 0.1455 0.3929 0.4000
p 0.0006 0.0238 0.0000 0.6696 0.3833 0.6000
Gaida et al. BMC Sports Science, Medicine and Rehabilitation  (2016) 8:5 Page 8 of 10decrease in IL-1β) in the female tendinopathy group, as
compared to the control female group. Such a difference
was not seen for males with tendinopathy compared to
control males. Similarly, the correlation between TNF-α
and physical activity that was seen in the male control
group was not seen for the female control group. Finally,
correlations between pairs of cytokines that were highly
correlated for men (TNF-α & bFGF, TNF-α & VEFG)
were not correlated among the female groups. This sug-
gests that separate analyses for men and women are im-
portant for future research on tendinopathy biomarkers.
This should be taken into consideration when doing fu-
ture studies on levels of cytokines and closely related
substances in relation to not only tendinopathy but also
various sports related activities and complaints (see [42]
for an overview of biomarkers in upper extremity mus-
culoskeletal disorders).
There are several limitations of this study that should
be acknowledged. First, this study had relatively small
cohorts of tendinopathy patients and controls, and
therefore may not have been adequately powered to de-
tect changes in the cytokines studied. Second, this clin-
ical cohort was heterogenous in terms of age, BMI and
duration of symptoms, however, the groups means were
actually well matched. Nevertheless, it is certainly pos-
sible that potential confounding factors not considered
may have influenced the results. This might for example
include menstrual cycle phases for women, which was
not measured in this study. Third, cytokine levels were
measured in serum and it is feasible that during process-
ing, activated platelets affected the cytokine profile in
the sample. It is also unknown to what extent serum
levels of cytokines reflect intratendinous or paratendi-
nous cytokine levels. While healthy tendons have a low
vascular supply, there is a markedly increased vascularsupply in chronic tendinopathy [43], and so the relation-
ship between tendon and serum cytokine levels may be
non-linear. However, all samples were taken at the same
time of day and processed identically. Fourth, all the par-
ticipants presented with chronic tendinopathy so at this
stage we don’t know anything about serum cytokine
levels in recently developed tendinopathy. Furthermore,
the details concerning the physical activity pattern the
days just before the day for the taking of the blood sam-
ple was not clarified; it was the general physical activity
pattern that was taken into consideration. Identifying
biomarkers of recently developed tendinopathy and in
relation to the physical activity pattern just before the
sample is taken are questions to be addressed in future
research projects.
Conclusion
This study identified lower serum TNF-α as a potential
tendinopathy biomarker among females but not males.
A lowering in PDGF-BB and a trend for a decrease in
IL-1β was also seen in the female tendinopathy group,
when compared to the female control group. A strong
correlation between physical activity level and serum
TNF-α was seen in the male control group but not the
male tendinopathy group, nor in any of the female
groups. Physical activity was also correlated with PDGF
and IL-1β for certain subgroups. BMI and pain symptom
duration were not associated with TNF-α, PDGF or IL-
1β for any of the groups, and therefore do not appear to
be confounding factors for these biomarkers in this
study. The findings suggest that various cytokine sys-
tems, including the TNF-α system, are related to the
presence of chronic Achilles tendinopathy. Further re-
search on biomarkers of tendinopathy should analyse
data for men and women separately and also
Gaida et al. BMC Sports Science, Medicine and Rehabilitation  (2016) 8:5 Page 9 of 10extensively measure physical activity levels both short
and long term.
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